Literature DB >> 8419408

Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle.

N Terada1, J J Lucas, A Szepesi, R A Franklin, J Domenico, E W Gelfand.   

Abstract

The effects of rapamycin (RAP) on cell cycle progression of human T cells stimulated with PHA were examined. Cell cycle analysis showed that the RNA content of cells stimulated with PHA in the presence of RAP was similar to that of control T cells stimulated with PHA for 12-24 hr in the absence of the drug. This level was substantially higher than that seen in cells stimulated in the presence of cyclosporin A (CsA), an immunosuppressant known to block cell cycle progression at an early point in the cycle. However, the point in the cell cycle at which RAP acted appeared to be well before the G1/S transition, which occurs about 30-36 hr after stimulation with PHA. In an attempt to further localize the point in the cell cycle where arrest occurred, a set of key regulatory events leading to the G1/S boundary were examined, including p110Rb phosphorylation, which occurred at least 6 hr prior to DNA synthesis, p34cdc2 synthesis, and cyclin A synthesis. In control cultures, p110Rb phosphorylation was detected within 24 hr of PHA stimulation; p34cdc2 and cyclin A synthesis were detected within 30 hr. Addition of RAP to the cultures inhibited each of these events. In contrast, early events, including c-fos, IL-2, and IL-4 mRNAs expression, and IL-2 receptor (p55) expression, were only marginally affected, if at all, in PHA-stimulated T cells. Furthermore, the inhibition of cell proliferation by RAP could not be overcome by addition of exogenous IL-2. These results indicate that RAP blocks cell cycle progression of activated T cells after IL-2/IL-2 receptor interaction but prior to p110Rb phosphorylation and other key regulatory events signaling G1/S transition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419408     DOI: 10.1002/jcp.1041540103

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  28 in total

1.  Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin.

Authors:  R Mendez; G Kollmorgen; M F White; R E Rhoads
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM.

Authors:  Yann Gouëffic; Susan Potter-Perigo; Christina K Chan; Pamela Y Johnson; Kathleen Braun; Steven P Evanko; Thomas N Wight
Journal:  Atherosclerosis       Date:  2006-12-14       Impact factor: 5.162

3.  Sirolimus-Loaded Intravitreal Implant for Effective Treatment of Experimental Uveitis.

Authors:  Mayara Rodrigues Brandão De Paiva; Daniel Vítor Vasconcelos-Santos; Lorena Carla Vieira; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

4.  Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation.

Authors:  Jane Bryant; Kelan A Hlavaty; Xiaomin Zhang; Woon-Teck Yap; Lei Zhang; Lonnie D Shea; Xunrong Luo
Journal:  Biomaterials       Date:  2014-07-25       Impact factor: 12.479

Review 5.  Current and emerging strategies for the prevention of graft-versus-host disease.

Authors:  Sung Won Choi; Pavan Reddy
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

6.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.

Authors:  M I Chiu; H Katz; V Berlin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.

Authors:  Mayara Rodrigues Brandão De Paiva; Nayara Almeida Lage; Maria Carolina Andrade Guerra; Marcos Paulo Gomes Mol; Marcela Coelho Silva Ribeiro; Gustavo De Oliveira Fulgêncio; Dawidson A Gomes; Isabela Da Costa César; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  Doc Ophthalmol       Date:  2018-11-19       Impact factor: 2.379

8.  Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

Authors:  Brian C Wulff; Jennifer M Thomas-Ahner; Jonathan S Schick; Tatiana M Oberyszyn
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

9.  Rapamycin unbalances the polarization of human macrophages to M1.

Authors:  Alessia Mercalli; Ines Calavita; Erica Dugnani; Antonio Citro; Elisa Cantarelli; Rita Nano; Raffaella Melzi; Paola Maffi; Antonio Secchi; Valeria Sordi; Lorenzo Piemonti
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

10.  Anti-proinflammatory effects of sirolimus on human islet preparations.

Authors:  Atsuyoshi Mita; Camillo Ricordi; Atsushi Miki; Scott Barker; Ross Haertter; Yasuhiko Hashikura; Shin-Ichi Miyagawa; George W Burke; Luca Inverardi; Hirohito Ichii
Journal:  Transplantation       Date:  2008-07-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.